Summary
The AI statements largely concern generic availability/manufacturers and a specific FDA approval date/indication; the provided FDA label excerpts do not address generic versions, manufacturing companies, or approval timing, so label-based support cannot be established for those claims. No label-supported prescribing content was substantively evaluated.
Category Scores
Accurate Statements
Unsupported Statements
Generic versions of Xarelto (rivaroxaban) are already available in the United States.
The provided XARELTO prescribing information excerpts do not mention generic availability in the US.
In February 2020, the FDA approved the first generic versions of Xarelto (rivaroxaban) for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
The provided label excerpts do not contain information about approval timing for generics or FDA actions regarding generic products.
The approved generic versions of Xarelto are manufactured by multiple pharmaceutical companies, including Mylan and Teva.
The provided label excerpts do not name generic manufacturers or list companies producing generic versions.
Contradictions
Important Omissions
Any dosing, contraindications, warnings/precautions, administration instructions, or safety monitoring content corresponding to XARELTO labeling.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Unknown
The evaluated statements are about generic availability/manufacturers and an approval date, which are not prescribing/safety instructions in the provided label excerpts; therefore, direct patient-safety impact relative to the provided label cannot be assessed.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Label excerpts provided do not support claims about generic availability, generic approval dates, or specific generic manufacturers.
Suggested Improvement
Audit prescribing-related claims (indications, dosing/administration, contraindications, boxed warnings, warnings/precautions, drug interactions, and monitoring) using the exact AI-generated text. Exclude or separately verify non-label regulatory/manufacturing statements using official FDA approval databases rather than the drug label excerpts.